Keyword search (3,619 papers available)


Large-scale mGluR5 network abnormalities linked to epilepsy duration in focal cortical dysplasia.

Author(s): DuBois JM, Mathotaarachchi S, Rousset OG, Sziklas V, Sepulcre J, Guiot MC, Hall JA, Massarweh G, Soucy JP, Rosa-Neto P, Kobayashi E...

To determine the extent of metabotropic glutamate receptor type 5 (mGluR5) network abnormalities associated with focal cortical dysplasia (FCD), we performed graph theoretical analysis of [11C]ABP6...

Article GUID: 33401137
Recommendations of the 5th Canadian Consensus Conference on the diagnosis and treatment of dementia.

Author(s): Ismail Z, Black SE, Camicioli R, Chertkow H, Herrmann N, Laforce R, Montero-Odasso M, Rockwood K, Rosa-Neto P, Seitz D, Sivananthan S, Smith...

Alzheimers Dement. 2020 Jul 29;: Authors: Ismail Z, Black SE, Camicioli R, Chertkow H, Herrmann N, Laforce R, Montero-Odasso M, Rockwood K, Rosa-Neto P, Seitz D, Sivananthan S, Smith EE, Soucy JP,...

Article GUID: 32725777
Topographical distribution of Aβ predicts progression to dementia in Aβ positive mild cognitive impairment

Author(s): Pascoal TA, Therriault J, Mathotaarachchi S, Kang MS, Shin M, Benedet AL, Chamoun M, Tissot C, Lussier F, Mohaddes S, Soucy JP, Massarweh G,...

INTRODUCTION: Abnormal brain amyloid beta (Aβ) is typically assessed in vivo using global concentrations from cerebrospinal fluid and positron emission tomography (PET). However, it is unknown...

Article GUID: 32582834
Metabotropic glutamate type 5 receptor binding availability during dextroamphetamine sensitization in mice and humans.

Author(s): Smart K, Nagano-Saito A, Milella MS, Sakae DY, Favier M, Vigneault E, Louie L, Hamilton A, Ferguson SSG, Rosa-Neto P, Narayanan S, El Mestik...

J Psychiatry Neurosci. 2020 Jun 19;45(4):190162 Authors: Smart K, Nagano-Saito A, Milella MS, Sakae DY, Favier M, Vigneault E, Louie L, Hamilton A, Ferguson SSG, Rosa-Neto P, Narayanan S, El Mesti...

Article GUID: 32559027
Non-invasive in vivo hyperspectral imaging of the retina for potential biomarker use in Alzheimer's disease.

Author(s): Hadoux X, Hui F, Lim JKH, Masters CL, Pébay A, Chevalier S, Ha J, Loi S, Fowler CJ, Rowe C, Villemagne VL, Taylor EN, Fluke C, Soucy JP, Les...

Nat Commun. 2019 Sep 17;10(1):4227 Authors: Hadoux X, Hui F, Lim JKH, Masters CL, Pébay A, Chevalier S, Ha J, Loi S, Fowler CJ, Rowe C, Villemagne VL, Taylor EN, Fluke C, Soucy JP, Lesage F, ...

Article GUID: 31530809
Inferior Longitudinal Fasciculus' Role in Visual Processing and Language Comprehension: A Combined MEG-DTI Study.

Author(s): Shin J, Rowley J, Chowdhury R, Jolicoeur P, Klein D, Grova C, Rosa-Neto P, Kobayashi E

Front Neurosci. 2019;13:875 Authors: Shin J, Rowley J, Chowdhury R, Jolicoeur P, Klein D, Grova C, Rosa-Neto P, Kobayashi E

Article GUID: 31507359
Metabotropic Glutamate Receptor Type 5 (mGluR5) Cortical Abnormalities in Focal Cortical Dysplasia Identified In Vivo With [11C]ABP688 Positron-Emission Tomography (PET) Imaging.

Author(s): DuBois JM, Rousset OG, Guiot MC, Hall JA, Reader AJ, Soucy JP, Rosa-Neto P, Kobayashi E

Cereb Cortex. 2016 10 17;26(11):4170-4179 Authors: DuBois JM, Rousset OG, Guiot MC, Hall JA, Reader AJ, Soucy JP, Rosa-Neto P, Kobayashi E

Article GUID: 27578494
Quantification of brain cholinergic denervation in Alzheimer's disease using PET imaging with [18F]-FEOBV.

Author(s): Aghourian M, Legault-Denis C, Soucy JP, Rosa-Neto P, Gauthier S, Kostikov A, Gravel P, Bédard MA

Mol Psychiatry. 2017 11;22(11):1531-1538 Authors: Aghourian M, Legault-Denis C, Soucy JP, Rosa-Neto P, Gauthier S, Kostikov A, Gravel P, Bédard MA

Article GUID: 28894304
Amyloid and tau signatures of brain metabolic decline in preclinical Alzheimer's disease.

Author(s): Pascoal TA, Mathotaarachchi S, Shin M, Park AY, Mohades S, Benedet AL, Kang MS, Massarweh G, Soucy JP, Gauthier S, Rosa-Neto P, Alzheimer’s ...

Eur J Nucl Med Mol Imaging. 2018 06;45(6):1021-1030 Authors: Pascoal TA, Mathotaarachchi S, Shin M, Park AY, Mohades S, Benedet AL, Kang MS, Massarweh G, Soucy JP, Gauthier S, Rosa-Neto P, Alzheim...

Article GUID: 29396637
Title:Metabotropic Glutamate Receptor Type 5 (mGluR5) Cortical Abnormalities in Focal Cortical Dysplasia Identified In Vivo With [11C]ABP688 Positron-Emission Tomography (PET) Imaging.
Authors:DuBois JM,  Rousset OG,  Guiot MC,  Hall JA,  Reader AJ,  Soucy JP,  Rosa-Neto P,  Kobayashi E
Link:https://www.ncbi.nlm.nih.gov/pubmed/27578494?dopt=Abstract
DOI:10.1093/cercor/bhw249
Category:Cereb Cortex
PMID:27578494
Dept Affiliation: PERFORM
1 Department of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University, 3801 University Street, Montreal, Quebec, Canada H3A 2B4.
2 Division of Nuclear Medicine and Molecular Imaging, Johns Hopkins University, Baltimore, MD 21287, USA.
3 Department of Pathology, McGill University, Montreal, Quebec, Canada H3A 2B4.
4 PET Unit, McConnell Brain Imaging Center, Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada H3A 2B4.
5 Division of Imaging Sciences and Biomedical Engineering, King's College London, St. Thomas' Hospital, London SE1 7EH, UK.
6 Bio-Imaging Group, PERFORM Centre, Concordia University, Montreal, Quebec, Canada H4B 1R6.
7 Translational Neuroimaging Laboratory, McGill Center for Studies in Aging, Douglas Mental Health University Institute, McGill University, Montreal, Quebec, Canada H4H 1R3.

Description:

Metabotropic Glutamate Receptor Type 5 (mGluR5) Cortical Abnormalities in Focal Cortical Dysplasia Identified In Vivo With [11C]ABP688 Positron-Emission Tomography (PET) Imaging.

Cereb Cortex. 2016 10 17;26(11):4170-4179

Authors: DuBois JM, Rousset OG, Guiot MC, Hall JA, Reader AJ, Soucy JP, Rosa-Neto P, Kobayashi E

Abstract

Metabotropic glutamate receptor type 5 (mGluR5) abnormalities have been described in tissue resected from epilepsy patients with focal cortical dysplasia (FCD). To determine if these abnormalities could be identified in vivo, we investigated mGluR5 availability in 10 patients with focal epilepsy and an MRI diagnosis of FCD using positron-emission tomography (PET) and the radioligand [11C]ABP688. Partial volume corrected [11C]ABP688 binding potentials (BPND) were computed using the cerebellum as a reference region. Each patient was compared to homotopic cortical regions in 33 healthy controls using region-of-interest (ROI) and vertex-wise analyses. Reduced [11C]ABP688 BPND in the FCD was seen in 7/10 patients with combined ROI and vertex-wise analyses. Reduced FCD BPND was found in 4/5 operated patients (mean follow-up: 63 months; Engel I), of whom surgical specimens revealed FCD type IIb or IIa, with most balloon cells showing negative or weak mGluR5 immunoreactivity as compared to their respective neuropil and normal neurons at the border of resections. [11C]ABP688 PET shows for the first time in vivo evidence of reduced mGluR5 availability in FCD, indicating focal glutamatergic alterations in malformations of cortical development, which cannot be otherwise clearly demonstrated through resected tissue analyses.

PMID: 27578494 [PubMed - indexed for MEDLINE]